Glucose Health, Inc.
Glucose Health, Inc. (GLUC): 2 pipeline candidates · ~35 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
34.9 months
D/E -1.06 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for Glucose Health, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$13.2M
Cash
$17K
Quarterly Burn
$2K
Runway
34.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| glucose health | Approved |
| type2 defense | — |
Frequently asked questions
How many drug candidates are in Glucose Health, Inc.'s pipeline?
Glucose Health, Inc. (GLUC) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Glucose Health, Inc.'s lead drug candidate?
Glucose Health, Inc.'s most advanced tracked candidate is glucose health (Approved) for pre-diabetes and Type-2 diabetes.
What is Glucose Health, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Glucose Health, Inc. has approximately 34.9 months of cash runway.
What is Glucose Health, Inc.'s market capitalization?
Glucose Health, Inc.'s market capitalization is approximately $13.2M.
Who is the CEO of Glucose Health, Inc.?
Mr. Mark D. Schaftlein is the chief executive officer of Glucose Health, Inc. (GLUC).
Get the full picture on Glucose Health, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.